Status
Conditions
Treatments
About
In this study, we will investigate the diagnostic efficacy and safety of [18F]F-H3RESCA-3A12 and [68Ga]Ga-NOTA-3A12 in metastatic gastric and pancreatic cancers, and evaluate the sensitivity and specificity of the use of [18F]F-H3RESCA-3A12 and [68Ga]Ga-NOTA-3A12 for diagnosing metastatic gastric and pancreatic cancers . This study will provide a new method for the noninvasive target-specific diagnosis of gastric and pancreatic cancer, and provide intuitive and clear imaging basis for clinical diagnosis, differential diagnosis and treatment.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
(1) Age between 18 and 65 years old, gender is not limited. (2) Patients with gastric or pancreatic cancer confirmed by puncture or surgical pathology.
(3) Written informed consent signed by the subject or his/her legal guardian or caregiver.
(4) Willingness and ability to cooperate with all programs of this study.
Exclusion criteria
(4) History of serious surgery in the last month. (5) Those who have participated in other clinical trials during the same period.
Primary purpose
Allocation
Interventional model
Masking
40 participants in 2 patient groups
Loading...
Central trial contact
Yihui Guan, MD
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal